SeekingAlphaAugust 23, 2026 at 1:52 AM NY12 days ago
Prelude Therapeutics: A Prognosis After Year-Long Rally
Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
Jim Cramer Thinks This Struggling Stock Could See A “Big Earnings Acceleration”
Yahoo2 hours ago
Walmart, Target, and Kroger face growing retail crime issue
Yahoo2 hours ago
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
Yahoo5 hours ago
Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run
Yahoo5 hours ago
Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks
Yahoo6 hours ago